Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

(S)-HDAC-42 is a histone deacetylase (HDAC) inhibitor (IC50 = 16 nM).1 It increases acetylation of histone H3 in DU145 prostate cancer cells when used at concentrations ranging from 0.1 to 2.5 µM. (S)-HDAC-42 decreases viability of DU145 cells (IC50 = 0.11 µM). It induces cell cycle arrest at the G1 phase in A2780 ovarian cancer cells when used at a concentration of 0.5 µM.2 (S)-HDAC-42 (25 mg/kg per day or 50 mg/kg every other day) decreases tumor volume in a PC3 prostate cancer mouse xenograft model.3
WARNING This product is not for human or veterinary use.
1. Structure-
2. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 11(6), 552-563 (2009).
3. Antitumor effects of a novel phenylbutyrate-